News | June 09, 2026
Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The safety profile was described as manageable, though not without notable toxicities
The approval is supported by results from the Phase 3 SWOG 1826 trial
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
The company’s Growth Portfolio delivered $6.2 billion in revenue
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
